CRIS - Multiplikator P/S Curis Corp
Curis, Inc. minimizes capital expenditures by outsourcing clinical trials to third-party organizations. The price-to-sales trend clearly demonstrates a smooth market valuation, where the parameter value equals 0.90. The company generates stable passive income from royalties for targeted therapy. However, a high dependence on the outcomes of a few drug trials creates significant binary risks for investors.
Curis, Inc. (CRIS) - rincian metrik lan laporan keuangan
- rega pasar lan target rega analis:
- statistik kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Koefisien Total Utang marang Modal Curis, Inc.|CRIS - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal curis.com|CRIS - Gunggung utang perusahaan|Utang-utang marang aset resik Curis Corp|CRIS - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Curis|Indikator likuiditas cepet curis.com
- informasi bathi lan kelipatan valuasi:
CRIS - Penghasilan resik|Prakiraan bathi perusahaan Curis, Inc.|CRIS - Pangali P/E|Prakiraan rega marang bathi curis.com|CRIS - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Curis Corp|CRIS - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Curis|CRIS - Bathi saben saham sajrone rolas wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan curis.com|CRIS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Curis, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:CRIS, Curis Inc.
Curis, Inc. (CRIS) focuses on high-tech developments in targeted oncology, where business value is driven by the potential of the R&D pipeline. This metric compares the company's market capitalization with its current revenues, quantifying market expectations regarding the future commercialization of drugs. The P/S ratio measures the premium investors are willing to pay per unit of revenue, identifying whether the asset is overvalued or undervalued. The price-to-sales ratio trend helps assess market optimism amid ongoing clinical trials.
Pesaing Curis, Inc.
Kapitalisasi marang pendapatan beigene.com ONC|Halozyme - Kapitalisasi marang pendapatan|Multiplikator P/S Revolution Medicines Inc RVMD|AAPG - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CGON (CG Oncology Therapeutics)|URGN: Multiplikator P/S|BCAX - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Personalis|Erasca Inc (ERAS) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan DCTH (Delcath)|YMAB (Y-mAbs Corp) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S AURA (Aura Biosciences, Inc.)|Koefisien rega marang pendapatan Candel Therapeutics Inc. (CADL)|ARAY - Rasio rega marang pendapatan|SLS (SELLAS Life Sciences) - Rasio kapitalisasi marang pendapatan|ACTU: Multiplikator P/S|Kapitalisasi marang pendapatan Citius Oncology Inc|Kapitalisasi marang pendapatan HURA|protaratx.com (TARA) - Koefisien rega marang pendapatan|Multiplikator P/S FATE|Kapitalisasi marang pendapatan aadibio.com WHWK|Rasio rega marang pendapatan TScan Therapeutics, Inc. TCRX|Rasio kapitalisasi pasar marang pendapatan CSBR|XBiotech USA - Multiplikator P/S|Koefisien rega marang pendapatan CEL-SCI Corporation CVM|OS Therapies (OSTX) - Rasio rega marang pendapatan|RADX - Koefisien rega marang pendapatan|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Adlai Nortye Limited (ANL)|Multiplikator P/S VERU|Multiplikator P/S tempesttx.com (TPST)|Rasio rega marang pendapatan Xilio Therapeutics XLO|RENB: Rasio kapitalisasi marang pendapatan|Mural Bio - Multiplikator P/S|Kairos Pharma Ltd (KAPA) - Kapitalisasi marang pendapatan|OKUR: Multiplikator P/S|Rega marang dodolan CytoMed Therapeutics Limited (GDTC)|Rasio rega marang pendapatan Apollomics Inc.|THAR: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan ADVB (Advanced Biomed Inc)|GNPX (Genprex Inc) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Kapitalisasi marang pendapatan|XBIO: Kapitalisasi marang pendapatan|SLRX - Multiplikator P/S|Purple Biotech Corp (PPBT) - Rasio rega marang pendapatan|American Oncology Network, Inc. - Rasio kapitalisasi pasar marang pendapatan|BGNE (BeiGene, Ltd.) - Multiplikator P/S|Rega marang dodolan checkpointtx.com CKPT|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan icadmed.com ICAD|Ikena Oncology - Kapitalisasi marang pendapatan|Multiplikator P/S Notable Labs Corp NTBL|VIRX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MOR (morphosys.com)|NAYA: Multiplikator P/S|AAPGV - Koefisien rega marang pendapatan
